JPRN-jRCT2031250820 Givastomig Liver metastases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines JPRN-jRCT2031250820 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 27 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why JPRN-jRCT2031250820 is a hot trial to watch
Liver metastases is being segmented by mechanism, treatment setting, geography and endpoint architecture. JPRN-jRCT2031250820 is notable because it evaluates Givastomig in a Phase 2 design sponsored by I-Mab Biopharma U.S. Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | JPRN-jRCT2031250820 |
| Official title | A Randomized, Multicenter, Open-Label, Phase 2 Study of Givastomig (TJ033721) in Combination with Nivolumab and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously Untreated CLDN18.2-Positive and PD-L1-Positive Locally Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma |
| Phase / status | Phase 2 / 募集中 |
| Intervention | Givastomig |
| Sponsor | I-Mab Biopharma U.S. Ltd. |
| Geography | United States, China, Japan |
| Enrollment | 180 |
| Primary endpoint | 主要評価項目： • PFS：RECIST v1.1に従ってBICRにより決定された、無作為化から６病勢進行発生までの期間、または何らかの原因による死亡までの期間のうち、いずれか先に発生した期間と定義される • 安全性データ：有害事象（AE）、重篤な有害事象（SAE）、特に注目すべき有害事象（AESI）の発生率、バイタルサイン、12誘導心電図（ECG）、臨床検査所見など。 |
| Endpoint time frame | Not reported |
| Primary completion / readout proxy | 2031-10-31 |
Protocol design and endpoint interpretation
The indexed record describes a Phase 2 study of Givastomig in Liver metastases.
Allocation is Randomized, masking is Open Label, and the intervention model is Parallel Assignment. Planned enrollment of 180 participants across United States, China, Japan shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- 主要評価項目： • PFS：RECIST v1.1に従ってBICRにより決定された、無作為化から６病勢進行発生までの期間、または何らかの原因による死亡までの期間のうち、いずれか先に発生した期間と定義される • 安全性データ：有害事象（AE）、重篤な有害事象（SAE）、特に注目すべき有害事象（AESI）の発生率、バイタルサイン、12誘導心電図（ECG）、臨床検査所見など。 (time frame not reported)
- ## Primary Outcomes 1. To compare progression-free survival (PFS) as assessed by blinded independent central review (BICR) between subjects receiving givastomig in combination with nivolumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX) or capecitabine plus oxaliplatin (CAPOX) and subjects receiving control treatment consisting of nivolumab plus mFOLFOX or CAPOX. 2. To evaluate the safety of givastomig in combination with nivolumab plus mFOLFOX or CAPOX. (time frame not reported)
Readout outlook and evidence gap
The current protocol points to 2031-10-31 as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Givastomig is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: I-Mab Biopharma U.S. Ltd. is resolved to a normalized organization record in United States. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
JPRN-jRCT2031250820 provides a focused lens on Liver metastases development. Its value will be determined by whether Givastomig can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
